GlassScriptPhysician profile
Amanda M Dixon
NPI 1053883751
$9,760.56
in general payments reported to CMS, 2019-2025
43 companies · $2,083 in 2025
The $2,083 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,752 · 2022: $1,007 · 2023: $2,496 · 2024: $2,422 · 2025: $2,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,952 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,952.37 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,612.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $730.56 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $710.66 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Almatica Pharma LLC | $680.90 | 2023-2025 | Loreev Xr, Teriparatide, Gralise |
| Lilly USA, LLC | $630.67 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Amarin Pharma, INC. | $417.83 | 2021-2023 | |
| Pfizer INC. | $328.17 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $320.56 | 2021 | |
| Tris Pharma INC | $304.09 | 2023-2025 | Dyanavel Xr |
| Amgen INC. | $299.31 | 2021-2025 | Otezla, Repatha, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $242.96 | 2023-2025 | Caplyta |
| Boston Scientific Corporation | $242.11 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $236.36 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $229.20 | 2023-2025 | Trulance, Xifaxan |
| Idorsia Pharmaceuticals US INC | $189.86 | 2022-2023 | Quviviq |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.